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A B S T R A C T
Background: Diabetes mellitus causes a substantial
increase in cardiovascular risk, which can only partly be
reduced by antihyperglycaemic treatment. We were
interested in whether improvement in glycaemic control
is associated with improvement of other cardiovascular
risk factors. Therefore, we studied among type 2 diabetic
patients the association between on the one hand changes
in glycaemic control and on the other hand within-subject
changes of both classic cardiovascular risk factors and less
conventional cardiovascular risk indicators that are typically
associated with type 2 diabetes (proinsulin, insulin, 
fibrinogen, von Willebrand factor and the urinary albumin-
creatinine ratio).
Methods: The 214 type 2 diabetic patients were randomly
assigned to either a strict fasting capillary glucose target
level (<6.5 mmol/l) or a less strict target (<8.5 mmol/l).
Duration of follow-up was two years. Since the interventions
did not yield statistically significant differences between
the treatment arms, we reanalysed the data focusing on
within-subject changes of cardiovascular risk factors and
indicators across tertiles of average HbA1c.
Results: Individuals in whom HbA1c decreased had
significant favourable concurrent changes in triglycerides,
total cholesterol, blood pressure, and in the albumin-
creatinine ratio in those who were normoalbuminuric at
baseline. In contrast, these individuals had unfavourable,
although not statistically significant, changes in HDL
cholesterol, proinsulin, insulin, fibrinogen and von
Willebrand factor. In the whole group, fibrinogen increased
more than could be expected on the basis of the relationship
between fibrinogen and age, namely from 3.5 ± 0.8 to 3.9
± 0.9 g/l (p value <0.01).
Conclusions: Our results suggest that improvement in
glycaemia in type 2 diabetes is associated with significant
favourable changes in triglycerides, total cholesterol,
blood pressure and, in normoalbuminuric individuals,
albumin-creatinine ratio. In contrast, it is not consistently
associated with favourable changes in some cardiovascular
risk indicators typically associated with diabetes, which
may in part explain why antihyperglycaemic treatment
does not clearly lower atherothrombotic disease risk.
© 2003 Van Zuiden Communications B.V. All rights reserved.
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O R I G I N A L  A R T I C L E
I N T R O D U C T I O N
Type 2 diabetes carries an increased risk of cardiovascular
disease, which is not fully explained by several well-
established risk factors (i.e., variables causally related to
cardiovascular disease) associated with type 2 diabetes.1,2
Hyperglycaemia, an important factor in causing micro-
angiopathy in type 1 and type 2 diabetes,3-6 is an additional
possible explanation for the enhanced cardiovascular risk.7-12
However, the United Kingdom Prospective Diabetes Study
(UKPDS) showed that over the first ten years after diagnosis,
intensive glucose-control treatment, when compared with
conventional treatment, reduced the frequency of micro-
vascular complications but not diabetes-related mortality or
myocardial infarction.13 Furthermore, the feasibility trial of
the Veterans Affairs Cooperative Study Group (VA CSDM),
which compared randomly allocated intensive and
conventional glycaemic control, showed a trend towards
an adverse effect of intensive glycaemic control on cardio-
vascular mortality.14
Another explanation for the excess cardiovascular risk in
type 2 diabetes may lie in less conventional cardiovascular
risk indicators (i.e., variables whose association with
cardiovascular disease may or may not be causal), such as
proinsulin and insulin levels, and haemostatic and
fibrinolytic abnormalities, which are typically associated
with type 2 diabetes. For example, high levels of fibrinogen
may partially explain the excess cardiovascular risk in
type 2 diabetes.15-17 In addition, cardiovascular risk may be
increased by high von Willebrand factor levels (vWf) and
microalbuminuria,18-25 which may both reflect endothelial
dysfunction.19,21,26
We present data on a well-defined cohort of 214 type 2
diabetic patients followed for two years. After the
baseline assessment, patients were randomly assigned to
either a strict fasting capillary blood glucose target level
(<6.5 mmol/l), or a less strict target (<8.5 mmol/l). This
study design allowed us to study the effects of two different
levels of treatment intensification and analyse the
associations between within-subject changes of glycaemia,
and changes in lipidaemia, blood pressure, proinsulin,
insulinaemia, plasma fibrinogen, plasma vWf, and the
urinary albumin-creatinine ratio (ACR). We were especially
interested in whether improvement in glycaemic control
was associated with improvement in these cardiovascular
risk factors and indicators. Because the diabetic state is
thought to be associated with an adverse cardiovascular
risk profile, in part through the effects of hyperglycaemia
(and insulin resistance), we reasoned that improvement
of glycaemic control might be associated with favourable
changes of cardiovascular risk factors and indicators. On
the other hand, lack of any such associations might to
some extent explain the inconsistent effects of improvement
of glycaemic control on risk of atherothrombotic disease.13,14
M A T E R I A L S  A N D  M E T H O D S
Design and measurements
Participants were treated by their own general practitioner
(GP). A single physician (FEEvdD) and a diabetes educator
performed three-monthly surveillance of treatment-related
parameters at the study centre. Results were sent to the
GP. The GP (and the patient) then decided whether a
subsequent treatment step according to a standard step-up
therapy regimen should be taken. Enrolment to the trial
was between June 1992 and December 1993, and the trial
ended in December 1995. The Ethical Review Committee
of the Free University Medical Centre approved the study
protocol. The study was approved and performed before
results of the UKPDS were reported.
The regimen was a slightly modified version of the practice
guidelines for type 2 diabetes of the Netherlands College
of General Practitioners.27 An additional feature of the
regimen was a stepwise protocol for initiation of insulin
therapy by the GP. The regimen had the usual build-up:
tablets in increasing doses up to their usual maximum
before other blood-glucose-lowering agents were added.
In patients with a body mass index ≥27 kg/m2, metformin
was the first step. If the assigned target values for glycaemic
control were not reached, a sulphonylurea (SU) – either
glibenclamide, gliclazide or glipizide – was added. In
patients with a body mass index <27 kg/m2 SU was the
first step. If the assigned target values were not reached
on tablets alone, bedtime intermediate-acting insulin was
added (and metformin, if any, discontinued). If target values
were not reached with this combination therapy, SU was
discontinued and twice-daily injections of a mixture of
short- and intermediate-acting insulin were started. If
glycaemic control remained poor, multiple insulin injection
therapy was considered.
Patients were randomly allocated to one of two groups,
which differed only in target values for fasting capillary
glucose levels. In ‘group 6’, fasting target values for capillary
blood glucose were near-normal glycaemia (<6.5 mmol/l).
In the other arm (‘group 8’), the fasting treatment target
was <8.5 mmol/l, a value considered to be ‘acceptable’.27
Participating GPs were instructed to refrain from any
further steps that might lower blood glucose as long as
glucose levels were below the allocated target values.
Further details of the study population have been described
in detail elsewhere.28 Briefly, 372 Caucasian subjects between
40 and 75 years, were invited. After exclusion of subjects
with comorbidity and those who were probably nondiabetic,
232 gave informed consent and participated in the study.
Three-monthly assessments included levels of glucose,
HbA1c and lipids, treatment modality, body mass index,
blood pressure and early morning ACR. Six-monthly
assessments included serum creatinine, proinsulin, insulin
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and fibrinogen. VWf was measured at baseline, at one and
at two years. Systolic and diastolic (Korotkoff V) blood
pressure were measured on the right arm of the seated
patient with a Hawksley random zero sphygmomanometer.
Laboratory assessments
All blood samples were taken in the fasting state. Serum and
plasma were stored at -20°C for assessment of proinsulin,
insulin and vWf, which took place after closure of the data
collection. All other assessments were performed on the
same day. Venous glucose was measured in sodium fluoride
plasma by the glucose dehydrogenase method (Merck,
Germany). HbA1c was determined in EDTA plasma by ion
exchange HPLC (reference range: 4.3 to 6.1%; Modular
Diabetes Monitoring System, BioRad, the Netherlands).
Immunospecific insulin and proinsulin were measured
in serum by double-antibody radioimmunoassays (lot
SP21, Linco Research, St Louis, USA for insulin, and Lilly
Laboratory for Clinical Research, Indianapolis, USA for
proinsulin).29 Serum total cholesterol, HDL cholesterol and
triglycerides were determined by enzymatic colorimetric
techniques (CHOD-PAP and CPO-PAP, Boehringer
Mannheim, Germany). LDL cholesterol was calculated
with the Friedewald formula (not for patients with TG
>8.0 mmol/l).30 Fibrinogen was determined in citrated
plasma by a spectrophotometric prothrombin time-derived
method (ACL 1000, Instrumentation Laboratory, the
Netherlands). VWf was determined in heparinised plasma
by an ELISA and expressed as a percentage of normal
pooled plasma (reference range: 50 to 150%).18,31,32
Urinary and serum creatinine levels were measured by a
modified Jaffé method (Boehringer Mannheim, Germany).
Urinary albumin was measured by an immunonephelo-
metric method (sensitivity limit: 6.2 mg/l; Beckman,
Ireland). For calculation of urinary ACR, we only used
early morning samples negative to dipstick tests for nitrite
and leucocytes (86% of all samples).
Statistical analysis
We studied the effects of the random assignment by
comparison of groups 6 and 8 at the last available
measurements, using t tests, 2 tests or Mann-Whitney U
tests. Comparison of baseline and follow-up measurements
were carried out using paired t tests, McNemar’s 2 tests
or Wilcoxon’s signed-rank tests.
Since the interventions did not yield statistically significant
differences between the treatment arms we reanalysed the
data focusing on within-subject changes in cardiovascular
risk factors and indicators in the entire cohort. Cohort
analysis of a randomised clinical trial (RCT) is legitimate,
because an RCT is a cohort, with intervention as a deter-
minant. Adjusting the analysis for the intervention (high
versus low target) eliminates possible bias caused by this
determinant.33 The cardiovascular risk factors and indicators
considered were proinsulin, insulin, lipids, blood pressure,
fibrinogen, vWf and ACR. Normoalbuminuria was
distinguished from microalbuminuria and albuminurea
using 3.5 mg/mmol as the cut-off.34
To study within-subject changes, change rates (slopes) were
calculated for each patient separately by linear regression
analysis based on all the available measurements.
Preliminary analyses showed that patients with less than
the full two years of follow-up were likely to confound
analyses. Therefore, we chose to confine all analyses using
these change rates to those patients who completed two
years of follow-up (n=166). Relations between change
rates of glycaemic parameters and change rates of outcome
measures were studied by univariate scatter diagrams, and
by partial correlations after adjustment for sex, diabetes
duration, and group 6 or 8. We also addressed these
associations by using analysis of variance (ANOVA) and
trend analysis, comparing the change rates of the outcome
measures across tertiles of HbA1c change rates. All
multivariate analyses were performed with and without
additional adjustment for change in body weight.
R E S U L T S
During the first year, ten patients found participation too
much of a burden, six moved and one died (7%). One
outlier (a woman with a BMI of 59) was excluded from the
analyses. Thus, 106 patients in group 6 and 108 patients in
group 8 were included in the analyses. During the second
year, 12 of these remaining 214 patients found further partici-
pation too burdensome and dropped out, eight were lost
to follow-up and two died. At closure of the data collection,
26 patients had not yet reached the two-year visit. Mean dur-
ation of follow-up at the time of the analysis was 22 months.
Table 1 shows the characteristics of the study population.
Fasting plasma glucose was significantly lower in group 6
as compared with group 8, but no clinically meaningful
contrast in HbA1c had been achieved at a mean follow-up
of 22 months. Furthermore, the difference in treatment
intensity did not yield statistically significant differences
between groups 6 and 8 at follow-up in any of the other
outcome measures. In the total population, glycaemic
control improved slightly from baseline to follow-up, as
reflected by lowering of the fasting glucose levels and
lower variability of mean HbA1c. Furthermore, total and
LDL cholesterol, and blood pressure decreased. In contrast,
body mass index, fibrinogen and ACR (increase), and HDL
cholesterol (decrease) deteriorated during follow-up. Fasting
serum insulin increased significantly due to 23 patients
starting insulin injections during follow-up. At baseline
16.5% of the participants were on antihypertensive
medication and 13.5% lipid-lowering medication, versus
24.1 and 16.7% at follow-up.
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We subsequently analysed changes in the outcome measures
in patients who had completed two years of follow-up
(n=166) by tertiles of change rates of HbA1c (table 2).
Results for tertiles of fasting glucose change rates were
similar (data not shown). Triglycerides (figure 1), total
cholesterol and blood pressure changed most favourably
in the tertile with the HbA1c decrease, as compared with
the other two tertiles. These associations could not be
ascribed to the prescription of more lipid-lowering agents
or antihypertensives in that tertile (data not shown). Only
in patients with an ACR <3.5 mg/mmol at baseline did
changes in ACR show a significant favourable association
with HbA1c change rates. Changes in vWf were minor
and not related to HbA1c change rates. Overall, fibrinogen
increased, but mainly in the lowest and middle tertiles of
HbA1c change (table 2 and figure 2). We checked whether
adjustment for weight change altered any of the relations
under study. This was not the case (data not shown).
As shown in tables 1 and 2, there were relatively large mean
changes in fibrinogen, which could not be explained by
changes in glycaemic control (table 2), or by changes in
the prevalence of smokers (data not shown). Upon further
Becker, et al. Improvement of glycaemic control in type 2 diabetes.
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Table 1
Characteristics at baseline and at follow-up in group 6 (n=106), group 8 (n=108) and the total population (n=214)
AT BASELINE AT FOLLOW-UP* TOTAL POPULATION
GROUP 6 GROUP 8 GROUP 6 GROUP 8 AT BASELINE AT FOLLOW-UP*
Sex (% male) 53 44 49
Age (years) 63.3 ± 8.4 63.3 ± 8.3 63.3 ± 8.3
Diabetes duration 3.4 (0.7-14.2) 3.2 (0.3-12.7) 3.3 (0.5-13.3)
Cardiovascular history† 21 23 26c 29c 22 28d
Hypertension‡ (% yes) 59 56 59 59 57 59
Smoker (%) 19 22 17 21 20 19
Treatment modality (%) d a,d d
Diet alone 32 37 8 30 35 19
Metformin (M) 4 2 7 5 3 6
Sulphonylurea (SU) 43 38 37 27 40 33
SU + M 8 7 21 14 8 17
Insulin (with or without SU) 14 17 26 25 15 26
Body mass index (kg/m2)
Men 27.9 ± 3.7 28.2 ± 3.7 28.4 ± 3.9d 28.3 ± 3.5 28.0 ± 3.7 28.4 ± 3.7c
Women 28.2 ± 5.9 29.8 ± 4.7 28.5 ± 5.6 30.2 ± 5.3 29.0 ± 5.4 29.4 ± 5.4c
Fasting plasma glucose (mmol/l) 9.4 ± 2.8 9.7 ± 3.3 8.8 ± 2.3 9.5 ± 3.3a 9.6 ± 3.1 9.2 ± 2.9
HbA1c (%) 7.2 ± 1.6 7.6 ± 1.9 7.2 ± 1.2 7.4 ± 1.4 7.4 ± 1.7 7.3 ± 1.3
HDL cholesterol (mmol/l) 1.11 ± 0.30 1.12 ± 0.26 1.02 ± 0.30d 1.06 ± 0.27d 1.11 ± 0.28 1.04 ± 0.29d
Triglycerides 2.2 ± 1.5 2.2 ± 1.6 2.2 ± 1.1 2.0 ± 1.1 2.2 ± 1.5 2.1 ± 1.1
Total cholesterol 6.3 ± 1.5 6.4 ± 1.1 5.9 ± 1.2d 6.0 ± 1.0d 6.3 ± 1.3 6.0 ± 1.1d
LDL cholesterol 4.1 ± 1.1 4.2 ± 0.9 3.9 ± 1.0d 4.0 ± 0.9d 4.2 ± 1.0 4.0 ± 1.0d
Systolic blood pressure (mmHg) 152 ± 25 149 ± 22 149 ± 23 145 ± 24c 150 ± 23 147 ± 23c
Diastolic blood pressure 84 ± 12 85 ± 12 83 ± 11 83 ± 12 84 ± 12 83 ± 12c
Insulin (pmol/l) (n=143) 71 (31-158) 67 (43-146) 79 (35-216)c 84 (43-200)c 69 (38-158) 81 (37-212)d
Pro-insulin (n=143) 3.9 (1.2-9.1) 4.8 (1.0-10.6) 4.1 (1.1-9.3) 4.5 (1.2-9.8) 4.3 (1.1-10.4) 4.4 (1.2-9.4)
Fibrinogen (g/l) (n=179) 3.5 ± 0.8 3.6 ± 0.8 3.9 ± 0.9d 3.9 ± 0.9d 3.5 ± 0.8 3.9 ± 0.9d
Von Willebrand factor (%) 128 ± 53 118 ± 48 123 ± 46 122 ± 52 123 ± 51 123 ± 49
Albumin-creatinine ratio (mg/mmol)
Baseline <3.5 (n=174) 0.8 (0.4-1.8) 0.8 (0.4-2.0) 0.8 (0.4-3.0) 0.8 (0.3-2.6) 0.8 (0.4-1.9) 0.8 (0.4-2.6)c
Baseline ≥3.5 (n=40) 8.3 (3.7-137) 10.5 (4.4-73) 9.1 (0.6-89) 7.3 (1.6-74) 9.4 (3.8-73) 8.1 (0.9-74)
Serum creatinine (mol/l)
ACR at baseline <3.5 85 ± 17 82 ± 13 89 ± 17c 85 ± 13c 84 ± 15 87 ± 15d
ACR at baseline ≥3.5 87 ± 16 87 ± 16 95 ± 24c 94 ± 19d 87 ± 16 94 ± 22d
Data are percentages, means ± standard deviations, or medians (10th-90th centile). HbA1c = glycated haemoglobin, ACR = albumin creatinine ratio. 
* Mean
duration of follow-up: 22 months, † cardiovascular history is defined as at least one of the following: myocardial infarction, angina pectoris, stroke, transient
ischaemic attack, and intermittent claudication, ‡ hypertension is defined as a systolic blood pressure >165 mmHg, and/or a diastolic blood pressure >90 mmHg
and/or blood pressure-lowering medication. a Group 6 versus group 8, p<0.05, c follow-up versus baseline, p <0.05, d follow-up versus baseline, p<0.01.
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analysis, there were significant baseline differences in
fibrinogen levels among patients on diet treatment, those
on tablets, and those using insulin, which remained
when adjusted for age, sex and diabetes duration. These
differences were still present at follow-up. Patients using
insulin had significantly higher fibrinogen levels than
those on diet, while those on tablets had intermediate
fibrinogen levels. From baseline to follow-up, fibrinogen
increased from 3.7 ± 0.9 to 4.3 ± 0.9 g/l (mean ± SD,
p=0.03) in patients who started insulin treatment (n=23),
and from 3.3 ± 0.6 to 3.8 ± 0.9 g/l (p<0.001) in those
who changed from diet alone to tablet treatment (n=35).
In the subgroup who retained baseline treatment throughout
the study (n=93), fibrinogen increased from 3.5 ± 0.8 to
3.8 ± 0.9 g/l (p=0.003). In contrast, in the subgroup who
stayed on diet treatment alone throughout the study
(n=37), fibrinogen remained unchanged (3.4 ± 0.7 g/l),
despite significant worsening of glycaemic control. Among
individuals who started insulin treatment at some point
during the observation period, the change in fibrinogen
levels (measured at 0, 6, 12, 18 and 24 months) was about
twice as large in the six-month interval in which the
Becker, et al. Improvement of glycaemic control in type 2 diabetes.
Table 2
Median baseline HbA1c and adjusted change rates of serum lipids, blood pressure, serum pro-insulin and insulin, plasma
fibrinogen and von Willebrand factor, and urinary albumin-creatinine ratio, according to tertiles of HbA1c change rate
during follow-up (n=166, two-year follow-up)
TERTILES OF HBA1C CHANGE RATE MEDIAN BASE- MEAN CHANGE RATES ACR*
(%/YEAR) LINE HBA1C (%) (/YEAR) OF (MG/MMOL)
MEDIAN CHANGE RATE N (10TH-90TH HDL TG TC LDL SBP DBP INSU- PRO- FIBRIN- VWF BASE- BASE-
(10TH-90TH CENTILE) CENTILE) (mM) (mM) (mM) (mM) (mm (mm LIN† I OGEN (%) LINE LINE
Hg) Hg) (pM) (pM) (g/l) <3.5 ≥3.5
-0.56 (-1.29- -0.19): decrease 55 8.3 (6.7-10.8) -0.034 -0.17 -0.27 -0.14 -2.6 -0.9 6.3 0.13 0.22 -3.6 -0.12 -0.58
0.11 (-0.08-0.26): stable 56 6.4 (5.5-9.1) -0.054 0.00 -0.11 -0.05 0.2 -0.8 4.8 -0.10 0.26 1.4 0.13 5.09
0.53 (0.29-0.99): increase 55 6.3 (5.5-8.3) -0.044 0.08 -0.08 -0.05 1.1 1.5 0.3 0.73 0.15 0.3 0.51 0.96
p trend NS 0.00 0.01 NS NS 0.04 NS NS NS NS 0.00 NS
p ANOVA NS 0.01 0.02 NS 0.03 NS NS NS NS NS 0.01 NS
All change rates of the outcome measures are adjusted for sex, diabetes duration, and randomisation group. Additional adjustment for change in body weight did
not make substantial differences in any of the analyses. HbA1c = glycated haemoglobin, HDL = HDL cholesterol, TG = triglycerides, TC = total cholesterol, 
LDL = LDL cholesterol, SBP/DBP = systolic/diastolic blood pressure, I = insulin, vWf = von Willebrand factor, ACR = albumin creatinine ratio, NS = not significant
(p>0.05). * Subdivided into ACR <3.5 (n=133) and ≥3.5 mg/mmol (n=33) at baseline, † patients on insulin therapy at baseline and (or) at follow-up were excluded
(n of those included: 32/46/38).
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Figure 1
Scatterplot of the change rate of HbA1c and the change
rate of triglycerides
r = Pearson’s correlation coefficient, p = p value corresponding to
Pearson’s correlation coefficient.
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Figure 2
Scatterplot of the change rate of HbA1c and the change
rate of fibrinogen
r = Pearson’s correlation coefficient, p = p value corresponding to the
Pearson’s correlation coefficient.
insulin was started (0.28 g/l) as in the six-month intervals
preceding and following the interval in which insulin was
started (0.14 g/l). For comparison, plasma glucose continued
to decrease after starting insulin, body mass index continued
to increase, triglycerides decreased and ACR decreased.
The vWf levels during the one-year interval with and without
the initiation of insulin treatment showed a slight increase
(7.2%) and a slight decrease (-5.2%), respectively. Changes
in HDL cholesterol were not clearly associated with any
specific treatment step.
The duration of storage of serum and plasma samples
(range: 18 to 48 months) did not significantly correlate
with the measured levels of insulin, proinsulin and vWf
(correlation coefficients: .01, .09, and .07, respectively).
This suggests that the quality of the blood samples did
not deteriorate significantly during storage at -20°C.
D I S C U S S I O N
No differences between the two intervention arms were
found, except for a slightly lower fasting plasma glucose
level. The lack of a greater contrast in fasting glucose levels,
and in HbA1c, may have been due to two obstacles. Firstly,
the eligibility criteria employed may not have been
sufficiently restrictive. Secondly, compliance with the study
protocol may not have been sufficient to achieve the desired
divergence between the treatment arms. Therefore, we
reanalysed our data and focused on the question whether
different levels of success in lowering the main parameter
of antihyperglycaemic treatment, HbA1c, would be
accompanied by different changes in various cardiovascular
risk factors and indicators. As expected, we found that
triglycerides, total cholesterol, blood pressure and ACR
(only when <3.5 mg/mmol at baseline) exhibited significantly
more favourable changes in the tertile with decreasing
HbA1c, compared with the other tertiles. In contrast,
these favourable changes were not found for proinsulin,
insulin, fibrinogen and vWf (table 2). For fibrinogen and
vWf, this is in accordance with earlier studies.35-37
Moreover, in the whole group, fibrinogen even showed a
significant increase. In conclusion, improvement of
glycaemic control – with the strategy employed, i.e. a
conventional step-up regime consisting of metformin or
sulphonylurea in increasing dosages and insulin if the
assigned target values were not reached with metformin or
sulphonylurea – was associated with concurrent favourable
changes in some, but not all, the cardiovascular risk factors
and indicators.
Our results concerning the favourable association of HbA1c
with ACR in those subjects without microalbuminuria
and the absence of such an association in those with
microalbuminuria are in accordance with findings in type
1 diabetes that intensified glycaemic control may not have
favourable effects on the progression of the urinary albumin
excretion rate once microalbuminuria exists.38 In addition,
Levin et al. reported that creatinine clearance among
subjects with microalbuminuria deteriorated more rapidly
than among subjects without microalbuminuria, regardless
of intensity of glycaemic treatment.39
Glycaemic changes were not significantly associated with
changes in fibrinogen. However, fibrinogen increased after
the initiation of insulin treatment (or after an increase of
pharmacological treatment in general). Adjustment for
diabetes duration, age and sex did not substantially affect
differences between those who started insulin and the
rest of the population (data not shown). Furthermore,
fibrinogen showed a gradual overall increase during the
study. However, the yearly change rate was far greater than
the relationship of fibrinogen with age in nondiabetics
would suggest (except in the subgroup who remained on
diet treatment alone throughout the study). In a cross-
sectional study, De Boever et al. found a 0.14 g/l increase
per ten years in a nondiabetic population aged between
35 and 59 years.40 These findings may be of particular
interest. Firstly, considerable variations in cardiovascular
event rates could be attributable to relatively small variations
in fibrinogen levels. Meade et al. have shown that a
fibrinogen level elevation of 0.6 g/l was associated with an
84% increased risk of stroke within the next five years.41
In addition, Danesh et al. showed, in a meta-analysis of
prospective studies, an 80% increased risk for coronary
heart disease for each increment in fibrinogen of 1.0 g/l.42
Secondly, the VA CSDM feasibility trial reported an
unexpectedly high incidence of cardiovascular events in a
group of male type 2 diabetic patients who started insulin
treatment.14 Fibrinogen level rose significantly in the first
year and returned to baseline at two years.43
Insulin and proinsulin have been recognised as potentially
atherogenic substances, although it is not clear whether
insulin by injection has effects comparable with those seen
in hyperinsulinaemia related to insulin resistance.44,45 A
study in the offspring of hypertensive men demonstrated
that fibrinogen is closely related to plasma insulin and
most components of the insulin resistance syndrome.46 In
contrast De Feo et al. demonstrated that induced insulin
deficiency was associated with an increase in fibrinogen,
suggesting an acute phase protein response.47 In vitro
experiments lend support to possible adverse effects of
proinsulin and insulin on fibrinolysis, acting via both
liver and endothelium.48 The present findings could be in
accordance with an effect of treatment intensification on
the production of fibrinogen by hepatocytes in vivo. In vitro
studies, however, have shown inconsistent results in this
respect. Incubation of hepatocytes with insulin for less
than 24 hours had no influence on fibrinogen synthesis,49,50
while studies with longer incubation showed no effect,51
decreased52 or increased fibrinogen synthesis.53 Moreover,
Becker, et al. Improvement of glycaemic control in type 2 diabetes.
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in our study fibrinogen change rate was not related to
insulin and proinsulin change rates (data not shown).
In sum, our data do not provide an explanation for the
fibrinogen changes that were observed.
In conclusion, our study suggests that further improvement
of glycaemic control in moderately well-controlled type 2
diabetes is not associated with concurrent favourable
changes in some cardiovascular risk indicators that are
typically associated with type 2 diabetes. We stress that
our findings on glycaemic control cannot be distinguished
from the therapeutic strategy employed, i.e. a conventional
step-up regime consisting of metformin or sulphonylurea
in increasing dosages and insulin if the assigned target
values were not reached. Therefore, we cannot exclude that
improvement of glycaemic control through other strategies
may yield better results in terms of cardiovascular risk
factor amelioration. Nevertheless, our findings may provide
a framework for understanding the disappointing effects
of intensified glycaemic control on risk of macrovascular
disease. Our finding that fibrinogen levels may increase
after starting insulin treatment of particular concern and
warrants further study.
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